Results

Total Results: 2,212 records

Showing results for "drug".

141. Finding Grey Literature Evidence and Assessing for Outcome and Analysis Reporting Biases When Comparing Medical Interventions: AHRQ and the Effective Health Care Program | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/methods-guidance-reporting-bias/methods
     December 01, 2019 - Food and Drug Administration. … Drug Approval Process Manufacturers are required to submit a New Drug Application to the FDA for all … The Drugs@FDA site may be searched by the generic or trade drug name (not drug class) for Statistical … Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and … Drug Effectiveness Review Project.

142. Arthritis-Psoriatric Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
     April 01, 2012 - 1 Comparative Effectiveness Review Number 54 Drug Therapy for Psoriatic Arthritis in Adults: Update … Food and Drug Administration (FDA) has approved adalimumab, etanercept, golimumab, and infliximab for … KQ 3: For patients with PsA, do drug therapies differ in harms, tolerability, patient adherence, or … KQ 4: What are the comparative benefits and harms of drug therapies for PsA in subgroups of patients … Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report.

143. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
     December 22, 2014 - In October 2014, a new sofosbuvir drug combination drug was approved (Harvoni; Gilead Sciences) that … It has also been approved as part of a fixed-dose combination with the drug ledipasvir, a drug that … purportedly has a low drug-drug interaction profile, which could support its use in patients with … Gilead gets U.S. approval to sell new hepatitis C drug: drug is seen building on the highly successful … Food and Drug Administration (FDA).

144. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-protocol.pdf
     November 03, 2011 - Food and Drug Administration (FDA) for migraine prevention in adults come from different drug classes … surveillance, or interactive drug monitoring. … , patient education, drug surveillance, or interactive drug monitoring) influence results? … , patient education, drug surveillance, or interactive drug monitoring) influence results? … Regulating off-label drug use--rethinking the role of the FDA.

145. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/juvenile-arthritis-dmards/research
     December 01, 2019 - There are few direct comparisons of DMARDs, and insufficient evidence to determine if any specific drug … or drug class has greater beneficial effects.

146. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1406.pdf
     January 01, 2020 - Food and Drug Administration (FDA) bioequivalence study data were available for a drug or a pilot was … Narcan: FDA drug overview. [internet]. Silver Spring (MD): U.S. … Food and Drug Administration (FDA) [accessed 2014 May 05]. [2 p]. … Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER); 2014 Apr 3. … Holder urges use of drug to combat heroin overdoses.

147. Treatment of Depression During Pregnancy and the Postpartum Period | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/depression-pregnancy-postpartum/research-protocol
     December 01, 2019 - that are compared with drug only interventions. … A vs. drug B)? … The combinations include: Using a second drug to augment the effects of the primary drug and comparing … A vs. drug B)? … The combination include: (a) Using a second drug to augment the effects of the primary drug and comparing

148. Dia 1 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
     January 01, 2011 - pressure high blood pressure No adverse events Out-of-Pocket Costs 5 US$ 3 US$ 5 US$ Drug … A Drug B Drug C All MCDA and CA methods decompose a decision problem into a set of criteria … pressure high blood pressure No adverse events Out-of-Pocket Costs 5 US$ 3 US$ 5 US$ Drug … A Drug B Drug C C1 = 0.5 C2 = 0.33 C3 = 0.17 L1.1 = 0.5 L1,2 = 0.25 L1,3 = 0.25 drug A

149. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pulmonary_hi_impact.pdf
     April 01, 2012 - to determine whether they are potential candidates for the drug. … Food and Drug Administration (FDA); 2010 Apr 9. 39 p. … Food and Drug Administration (FDA); 2010 Apr 27. 35 p. … Available: http://www.vrtx.com/current-projects/drug- candidates/vx-770.html. 23. … /drug-candidates/vx-770.html http://investors.vrtx.com/releasedetail.cfm?

150. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics – Update | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/atypical-antipsychotics-off-label-update/research-protocol
     March 01, 2020 - Objectives for the Systematic Review Atypical antipsychotics are approved by the United States Food and Drug … To arrive at a quantitative measure, we will use the Jadad scale, which was developed for drug trials … The evidence of risks (adverse events) will be summarized within drug (each atypical antipsychotic separately … severely symptomatic persons have higher scores, a negative effect size indicates that the atypical drug

151. Communicating Harms and Benefits of Prescription Drugs to Healthcare Consumers (ppt file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/communicating_risk_hickam.ppt
     December 01, 2006 - practice & research Morning Presentations Innovative Methods of Communicating Harms and Benefits of Drug

152. Survey of Medicare Part D Plans’ Medication Therapy Management Programs (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research-2007.pdf
     January 01, 2007 - Plans (PDP) and Medicare Advantage Drug Plans (MA-PD). … Role of the clinical pharmacist in improving drug therapy. … Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001;250(4):327-41. 19. … Adverse drug events in emergency department patients. … for and/or existence of drug-drug, drug- disease, or drug-food interactions or problems) 55.0 5.6

153. Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/alzheimers-type-dementia/research
     October 01, 2022 - cognitive impairment; biomarker accuracy for Alzheimer’s disease (AD) in dementia; and effects of CATD drug … Cholinesterase-inhibitors slightly outperformed placebo for cognition and function, but evidence of whether any drug

154. Ventricular Arrhythmias and Cerebrovascular Events in the Elderly Using Conventional and Atypical Antipsychotic Medications | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/antipsychotic-medicine-cardiovascular-elderly/research
     January 01, 2020 - Reasons for using both drug groups (e.g., dementia, delirium) may themselves be risk factors for these … just new users to guard against selection bias among prevalent users from early symptom emergence, drug … models using propensity score adjustments to balance independent risk factors for outcomes between drug … Food and Drug Administration. … Available at: www.fda.gov/cder/drug/advisory/antipsychotics.htm . Accessed April 15, 2005. 2.

155. Community Pharmacy/Call Center Assessment of Medication Effectiveness & Safety | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/medicine-safety-call-center/research
     November 01, 2017 - An information technology architecture for drug effectiveness reporting and post-marketing surveillance … Abstract Adverse drug events impose a large cost on the society in terms of lives and healthcare costs … this paper, we propose an information technology architecture for enabling the monitoring of adverse drug … The proposed system architecture enables the development of a web based drug effectiveness reporting … previous studies analyzing the involvement of community pharmacies in identifying and reporting adverse drug

156. Joint Disorders | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/joint-disorders
     May 24, 2017 - medlineplus.gov/jointdisorders.html Products Research Protocol May 24, 2017 Drug … for Knee Pain Secondary to Osteoarthritis Systematic Review Archived June 1, 2012 Drug … Rheumatoid Arthritis in Adults: An Update Systematic Review Archived June 1, 2012 Drug … Report Research Protocol Archived December 6, 2010 Comparative Effectiveness of Drug … Arthritis Systematic Review Archived November 19, 2007 Comparative Effectiveness of Drug

157. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
     March 01, 2013 - Psoriatic Arthritis Surveillance Assesment_CER 54_Low CER #54: Drug Therapy for Psoriatic Arthritis … Key Findings: - Key Question 1: Conclusion regarding biologic Disease- Modifying Antirheumatic Drug … This drug is not approved for PsA. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date. … Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report.

158. Medication-Therapy-Management Research-Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/medication-therapy-management_research-protocol.pdf
     January 01, 2014 - Background and Objectives for the Systematic Review The Medicare Prescription Drug, Improvement, … Public Law 108-173)1 established the requirements that Part D plan sponsors must meet with regard to drug … include providing education and counseling, improving medication adherence, and detecting adverse drug … substitution issue; complex regimen that can be simplified with same therapeutic benefit; and potential for drug-drug … : needed drug initiated; unnecessary drug discontinued; change in drug dose, form, or frequency; or

159. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/substanceabuse_hi_impact.pdf
     January 01, 2012 - Food and Drug Administration (FDA) in October 2011 about preparing its new drug application and the … National Institute on Drug Abuse (NIDA). Prescription drugs: abuse and addiction. [internet]. … Food and Drug Administration. [internet]. … Food and Drug Administration. [internet]. … [internet]. drug- rehabs.com; [accessed 2011 Jan 5]. [3 p].

160. Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_policymaker.pdf
     August 01, 2016 - Food and Drug Administration for AUD include acamprosate (Campral®, thrice daily), disulfiram (Antabuse … Food and Drug Administration as treatment for alcohol dependence, alcohol abuse, or AUD.